Search results for "tips"

showing 10 items of 280 documents

Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis

2021

Background: Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited. Aims: Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database. Methods: A large therapeutic drug monitoring dataset of clozapine plasma concentrations considering three patient subgroups was analysed: a control group (CLZ0, 20–30 kg/m2, n=266), a group with high body mass index (CLZhigh, body mass index ⩾30 kg/m2, n=162) and with low body mass index values (CLZlow, body mass index <20 kg/m2, n=27). Comparisons of plasma and dose-adjusted plasma concentrations (C/D) of clozapine…

AdultMaleBiological AvailabilityPharmacologyBody weightBody Mass IndexYoung Adult03 medical and health sciencesSex Factors0302 clinical medicinePharmacokineticsmedicineHumansTissue DistributionPharmacology (medical)ObesityClozapineClozapineAgedRetrospective StudiesA determinantAged 80 and overPharmacologymedicine.diagnostic_testbusiness.industryBody WeightMiddle Agedmedicine.diseaseObesity030227 psychiatryPsychiatry and Mental healthAdipose TissueLiverTherapeutic drug monitoringPlasma concentrationFemaleDrug MonitoringbusinessBody mass index030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Psychopharmacology
researchProduct

Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects

2007

Aripiprazole, a novel antipsychotic drug, is metabolized by CYP3A4 and CYP2D6 forming mainly its active metabolite dehydroaripiprazole. In this study, aripiprazole and dehydroaripiprazole serum levels of psychiatric patients were measured and related to dose, comedication, and clinical effects including therapeutic and side effects. Patients were treated with mean doses of 20 +/- 8 mg/day of aripiprazole (median 15 mg, range 7.5-60 mg). Serum levels correlated significantly with the dose (r = 0.419; P0.01), with a mean value of aripiprazole of 214 +/- 140 ng/ml. Mean concentrations of the active metabolite dehydroaripiprazole amounted to 40% of the parent compound. Comedication with CYP3A4 …

AdultMaleCYP2D6AripiprazoleQuinolonesPharmacologydigestive systemPiperazinesCytochrome P-450 CYP3AHumansMedicineAntipsychotic drugskin and connective tissue diseasesDehydroaripiprazoleBiological PsychiatryActive metaboliteAgedCYP3A4medicine.diagnostic_testbusiness.industryMiddle AgedPsychiatry and Mental healthCytochrome P-450 CYP2D6Therapeutic drug monitoringSchizophreniaFemaleAripiprazolebusinessAntipsychotic Agentsmedicine.drugThe World Journal of Biological Psychiatry
researchProduct

Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas

2010

Quetiapine is next to clozapine an antipsychotic agent that exerts hardly any extrapyramidal side-effects at clinical efficacious doses. Some previous receptor occupancy studies reported preferential extrastriatal D2/3 receptor (D2/3R)-binding properties of second-generation antipsychotics and suggested this as possible reason for improved tolerability. This positron emission tomography (PET) investigation was designed to compare the occupancy of dopamine D2/3Rs by quetiapine in striatal and extrastriatal brain regions. Therefore, a cohort of 16 quetiapine-treated psychotic patients underwent an [18F]fallypride (FP) PET scan. Due to the high affinity of FP and its comparatively long half-li…

AdultMaleDibenzothiazepinesPyrrolidinesCaudate nucleusPharmacologyBinding CompetitiveQuetiapine FumarateYoung AdultQuetiapine FumarateDopamine receptor D2HumansMedicinePharmacology (medical)ClozapineVisual CortexPharmacologyTemporal cortexReceptors Dopamine D2business.industryReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumTemporal LobePsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesSchizophreniaQuetiapineFemalebusinessAntipsychotic Agentsmedicine.drugThe International Journal of Neuropsychopharmacology
researchProduct

Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year r…

2009

BackgroundEmpirical evidence of the efficacy and effectiveness of psychosocial family intervention and of the specificity of its effects on the course of schizophrenia is limited. The aim was to study the efficacy and effectiveness of psychosocial family intervention with regard to clinical and social functioning and family burden after controlling for compliance and several prognostic factors.MethodA 2-year randomized controlled trial with blind assessments. Fifty patients with DSM-IV schizophrenia and persistent positive symptoms and/or previous clinical relapse were allocated to psychosocial family intervention, individual counselling and standard treatment versus individual counselling …

AdultMaleFamily therapymedicine.medical_specialtylaw.inventionYoung AdultCost of IllnessRandomized controlled triallawIntervention (counseling)Secondary PreventionmedicineHumansSchizophreniform disorderPsychiatryApplied PsychologyPsychiatric Status Rating ScalesStandard treatmentSocial environmentmedicine.diseaseCombined Modality TherapyPsychotherapyPsychiatry and Mental healthTreatment OutcomeCaregiversPsychotic DisordersSpainSchizophreniaSchizophreniaPatient ComplianceFamily TherapyFemaleSchizophrenic PsychologyPsychologySocial AdjustmentPsychosocialAntipsychotic AgentsPsychological Medicine
researchProduct

Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study

2016

Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition. Several brain regions have been implicated in social cognition, including the nucleus caudatus, prefrontal and temporal cortex, and cerebellum. Oxytocin is a critical modulator of social cognition and the formation and maintenance of social relationships and was shown to improve symptoms and social cognition in schizophrenia patients. However, it is unknown whether the oxytocin receptor is altered in the brain. Therefore, we used qRT-PCR and Ornithine Vasotocin Analog ([125I]OVTA)-based receptor autoradiography to investigate oxytocin receptor expression at both the mRNA and protein level in the left p…

AdultMaleGene ExpressionVasotocinReal-Time Polymerase Chain ReactionLeft nucleusRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHaloperidolAnimalsHumansRNA MessengerClozapineBiological PsychiatryClozapineAgedAged 80 and overTemporal cortexBinding SitesBrainMiddle Agedmedicine.diseaseOxytocin receptor030227 psychiatryPsychiatry and Mental healthchemistryOxytocinReceptors OxytocinSchizophreniaSchizophreniaAutoradiographyHaloperidolFemalePsychologyNeurosciencehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugSchizophrenia Research
researchProduct

Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers

2002

The increased rate of smoking in schizophrenia patients remains unexplained and may reflect attempts at self-treatment. The effect sought from smoking may be related to nicotine's stimulating action. We tested this hypothesis by examining the relationship between smoking status and finger tapping rate, a measure of central processing, in schizophrenia patients treated with atypical antipsychotics. Smokers showed significantly faster finger tapping rates than non-smokers. This was not related to clinical state, illness chronicity, medication side-effects, antipsychotic dose or plasma concentrations. Nicotine can improve central processing in medicated schizophrenia patients and this may cons…

AdultMaleNicotinemedicine.medical_specialtyPatientsMovementmedicine.medical_treatmentClinical stateFingersNicotineInternal medicinemedicineHumansPharmacology (medical)Nicotinic AgonistsAntipsychoticPsychiatryBiological PsychiatryPharmacologySmokeAnalysis of VarianceSmokingMiddle Agedmedicine.diseasePsychiatry and Mental healthNeurologySchizophreniaFinger tappingPlasma concentrationSchizophreniaSmoking statusNeurology (clinical)PsychologyPsychomotor Performancemedicine.drugEuropean Neuropsychopharmacology
researchProduct

High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.

2003

The 'atypicality' of the antipsychotic drug, amisulpride, has been attributed to preferential extrastriatal binding. Previous investigations of striatal D2 receptor occupancy by amisulpride revealed conflicting results. The aim of this PET study was to measure the striatal occupancy by amisulpride and to correlate it with the corresponding drug plasma concentrations. Nine amisulpride-treated patients and 12 healthy volunteers serving as controls were studied with PET and [18F]desmethoxyfallypride. Occupancy values and plasma concentrations were nonlinearly fitted to an E max model. Results showed 43-85% (putamen) and 67-90% (caudate) D2-like receptor occupancy. Plasma amisulpride concentrat…

AdultMaleOccupancyPharmacologyDopamine receptor D2Image Interpretation Computer-AssistedSalicylamidesmedicineHumansPharmacology (medical)AmisulprideReceptorPharmacologyCerebral CortexChemistryReceptors Dopamine D2PutamenDesmethoxyfallypridePutamenMiddle Agedmedicine.diseaseNeostriatumPsychiatry and Mental healthSchizophreniaDopamine receptorArea Under CurvePositron-Emission TomographySchizophreniaFemaleAmisulprideCaudate NucleusRadiopharmaceuticalsSulpirideAlgorithmsmedicine.drugAntipsychotic AgentsThe international journal of neuropsychopharmacology
researchProduct

Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

2004

Background It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treat…

AdultMaleOlanzapineAdolescentPolysomnographymedicine.medical_treatmentPolysomnographySeverity of Illness IndexDrug Administration ScheduleBenzodiazepinesSurveys and QuestionnairesmedicineHumansPharmacology (medical)AntipsychoticSleep disorderSleep Stagesmedicine.diagnostic_testElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseSleep in non-human animalsDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthDelta RhythmOlanzapineSchizophreniaAnesthesiaDelta RhythmSchizophreniaSchizophrenic PsychologySleep StagesPsychologyAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables

2012

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remis…

AdultMaleOlanzapinePediatricsmedicine.medical_specialtymedicine.medical_treatmentLogistic regressionSeverity of Illness IndexTime-to-TreatmentBenzodiazepinesYoung AdultRisk FactorsmedicineHumansLongitudinal StudiesAntipsychoticPsychiatryBiological PsychiatryFirst episodeRisperidoneRemission InductionPrognosisRisperidonemedicine.diseaseClinical trialPsychiatry and Mental healthLogistic ModelsPsychotic DisordersOlanzapineSchizophreniadupSchizophreniaEducational StatusHaloperidolFemaleSchizophrenic PsychologyPsychologyAntipsychotic Agentsmedicine.drugPsychiatry Research
researchProduct

Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Me…

2019

Background Impaired subjective well-being in schizophrenia patients treated with antipsychotics has often been linked inter alia to the antidopaminergic effects of medication. Thus, it is important to capture the association between striatal dopamine D2 receptor occupancy (D2-RO) and global subjective well-being. We examined this association using data from our multicenter, randomized, double-blind Neuroleptic Strategy Study (NeSSy). Methods An innovative double randomization process was used for allocation of patients to the specific treatment groups. Plasma drug concentrations were measured after 6 and 24 weeks of treatment to obtain the estimated D2-RO (eD2-RO) relative to literature val…

AdultMaleOlanzapinemedicine.medical_specialtymedicine.medical_treatmentAripiprazolePersonal SatisfactionMedication Adherencelaw.invention03 medical and health sciencesSex Factors0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHaloperidolHumansPharmacology (medical)AntipsychoticReceptors Dopamine D2business.industryMiddle Agedmedicine.disease3. Good health030227 psychiatryFlupentixolFlupenthixolDopamine D2 Receptor AntagonistsPsychiatry and Mental healthOlanzapineSchizophreniaQuality of LifeSchizophreniaHaloperidolQuetiapineFemaleSchizophrenic PsychologyAripiprazolebusiness030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct